Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

NCT07704177 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms Immunotherapy

Interventions

DRUG: Trastuzumab Rezetecan
DRUG: Adebrelimab
DRUG: Lenvatinib

Sponsor

Peking Union Medical College Hospital